J&J (JNJ) Gears Up to Report Q4 Earnings: What's in Store?

Johnson & Johnson (JNJ) will report fourth-quarter and full-year 2023 results on Jan 23, before market open. In the last reported quarter, the company delivered an earnings surprise of 5.56%.Factors to ConsiderJ&J’s Innovative Medicines segment (previously the Pharmaceutical segment) sales are expected to have been driven by higher sales of key products such as Darzalex, Stelara, Tremfya and Erleada due to strong market growth and demand trends.The Zacks Consensus Estimate for Darzalex is pegged at $2.50 bi ...